• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home StudyGraphics

#VisualAbstract: Colchicine may lower the risk of cardiovascular events in patients with coronary disease

byConstance Wu
September 10, 2020
in StudyGraphics
Reading Time: 3 mins read
#VisualAbstract: Serum IL-6 and TNF-α levels identified as independent predictors of COVID-19 severity and mortality
Share on FacebookShare on TwitterShare on LinkedIn

1. Patients who received low-dose colchicine daily had a ~30% lower risk of cardiovascular events compared to those who received placebo.

2. Although the incidence of cardiovascular death was similar between groups, the colchicine group had a numerically greater number of non-cardiovascular deaths as well as all-cause deaths compared to the placebo group.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Colchicine is an anti-inflammatory drug that exerts its effects through inhibition of microtubule assembly, thereby reducing inflammasome activation and modulating leukocyte responsiveness. The Colchicine Cardiovascular Outcomes Trial (COLCOT) found that daily use of colchicine soon after myocardial infarction reduced the risk of further ischemic cardiovascular events and the previous Low-Dose Colchicine (LoDoCo) pilot trial found that patients with stable coronary disease who received colchicine were significantly less likely to experience acute cardiovascular events compared to those who did not. This randomized, placebo-controlled trial, termed LoDoCo2, confirmed the association between colchicine use and decreased risk of cardiovascular events using a patient population that was roughly 10 times larger than the first. This benefit became detectable early in the study and persisted with no attenuation over 5 years of treatment. Adverse events such as cancer, infection, pneumonia, and gastrointestinal upset occurred at similar rates between groups. While not quite statistically significant, the incidence rate of non-cardiovascular death was higher in the colchicine group compared to placebo. This study circumvented many weaknesses of the original LoDoCo trial, including a small sample size and the lack of placebo control, but some limitations still remained, such as the lack of data on blood pressure, lipid levels, and biomarkers of inflammation. Overall, the results of the LoDoCo2 trial lend further support to the effectiveness of colchicine in reducing the occurrence of cardiovascular events in patients with chronic coronary disease.

Click here to read the study, published today in NEJM

Relevant Reading: Low-Dose Colchicine for Secondary Prevention of Cardiovascular Disease

RELATED REPORTS

Pelacarsen lowers lipoprotein(a) but does not reduce major cardiovascular events in patients with established cardiovascular disease

Use of colchicine is not associated with reduced cardiovascular events among Chinese adults starting urate-lowering therapy

In-Depth [randomized controlled trial]: In this multicenter study beginning in August 2014, 5222 patients between 35 and 82 years of age with evidence of coronary disease entered a 1-month open-label run-in phase before being randomly assigned in a 1:1 ratio to either continue receiving 0.5 mg colchicine daily or begin receiving placebo. Patients with moderate-to-severe renal impairment, severe heart failure, or severe valvular heart disease were excluded. The primary endpoint, a composite of cardiovascular death, spontaneous myocardial infarction, ischemic stroke, and ischemia-driven coronary revascularization, occurred in 187 patients (6.8%) in the colchicine group and 264 patients (9.6%) in the placebo group (incidence, 2.5 vs. 3.6 events, respectively, per 100 person-years; hazard ratio [HR], 0.69; 95% confidence interval [CI], 0.57 to 0.83; P<0.001). This effect was consistent across subgroups defined according to age, sex, smoking status, diabetes, renal function, hypertension, and statin dose. Between-group differences were also detected in the first five pre-ranked secondary endpoints, all of which were different combinations of the individual components noted above (P<0.01 for all). However, both groups had similar cardiovascular mortality (20 vs. 25 fatalities; HR, 0.80; 95% CI, 0.44 to 1.44), non-cardiovascular mortality (53 vs. 35 fatalities; HR, 1.51; 95% CI, 0.99 to 2.31), and all-cause mortality (incidence, 0.9 vs. 0.8 events, respectively, per 100 person-years; HR, 1.21; 95% CI, 0.86 to 1.71).

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: cardiovascularcardiovascular eventscardiovascular mortalitycardiovascular riskcolchicineCoronary artery disease
Previous Post

Angiotensin II infusion for refractory shock associated with improved hemodynamic stability and decreased vasopressor requirement

Next Post

#VisualAbstract: Proadrenomedullin predicts severe community-acquired pneumonia among children

RelatedReports

A senior woman looks thoughtfully at a balance scale with a stethoscope and a heart illustration, symbolizing the assessment of cardiovascular risk and treatment decisions.
Cardiology

Pelacarsen lowers lipoprotein(a) but does not reduce major cardiovascular events in patients with established cardiovascular disease

November 14, 2026
Heart attack collage: a coronary artery ring of layered teal and blue paper with a pale plaque crescent and a ribbon through
Cardiology

Use of colchicine is not associated with reduced cardiovascular events among Chinese adults starting urate-lowering therapy

November 11, 2026
A profile of a human head with a visible brain, surrounded by descending bar graphs and doors leading into a fading background, suggesting themes of dementia and cognitive decline.
Weekly Rewinds

2 Minute Medicine Rewind November 9, 2026

November 11, 2026
Cannabis and mental health collage: a thoughtful young man with curly hair, a flat cannabis leaf and three blank shopfronts
Cardiology

Cannabis use, including smoked or edible, linked to higher stroke risk

November 6, 2026
Next Post
#VisualAbstract: Serum IL-6 and TNF-α levels identified as independent predictors of COVID-19 severity and mortality

#VisualAbstract: Proadrenomedullin predicts severe community-acquired pneumonia among children

No significant differences in outcomes between pre- and post-treatment administration of P2Y12 inhibitors for NSTE-ACS

#VisualAbstract: Serum IL-6 and TNF-α levels identified as independent predictors of COVID-19 severity and mortality

#VisualAbstract: Serum IL-6 and TNF-α levels identified as independent predictors of COVID-19 severity and mortality

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Medicaid-reimbursed weight-loss GLP-1 prescriptions fell after coverage withdrawal in 4 states
  • Social isolation and loneliness is associated with worse physical and mental health among middle-aged and older adults
  • Gait analysis predicts health, sleep, and medication use across 18 body systems
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.